• HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)

  NCT05775965

  RecruitingInterventionalPhase 2Updated Jan 14, 2025
• ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty

  NCT06611319

  RecruitingInterventionalPhase 3Updated Jan 16, 2025
• Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

  NCT01776424

  CompletedInterventionalPhase 3Updated Nov 28, 2022
• Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty

  NCT01720108

  CompletedInterventionalPhase 3Updated Jan 25, 2018
• VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

  NCT06873321

  RecruitingInterventionalPhase 4Updated Mar 12, 2025
• VTE Prevention Following Total Hip and Knee Arthroplasty

  NCT04075240

  CompletedInterventionalPhase 3Updated Jun 16, 2026

ClinicalTrials.gov ID

NCT07228663

Lead Sponsor

McMaster UniversityOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

100Estimated

Last Update Posted

Nov 14, 2025Actual

Start Date

Dec 1, 2025Estimated

Primary Completion Date

Jul 1, 2027Estimated

Completion Date

Dec 1, 2027Estimated

Official Title

Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial

Brief Summary

A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.

• Hip Fracture Surgery
• Cardiovascular Prevention
• Venous Thromboembolism (VTE)

• rivaroxaban and ASA
• Low-molecular weight heparin
• Fondaparinux
• Direct Oral Anticoagulant (DOAC)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age ≥45 years, received surgery for a hip fracture due to a low-energy mechanism, and myocardial injury (i.e., an elevated troponin measurement).

Exclusion Criteria:

• Centers in which standard of care for VTE prophylaxis after hip fractures is ASA, alone or in combination with other drugs; patients with GFR <15mL/min; patients with drug interactions and conditions that prevent the use of the standard of care or intervention [Known allergy to the study drugs; pregnancy; an indication for anticoagulation, for dual antiplatelet therapy, for a P2Y12 inhibitor; already on rivaroxaban 2.5 mg twice daily + ASA before the fracture; bleeding diathesis that in the judgment of the investigator precludes the use of anticoagulant prophylaxis; history of significant hepatic disease (Child-Pugh B or C, see supplementary material) or any other condition that, in the judgment of the investigator, precludes the use of rivaroxaban; concomitant use of drugs that are strong inhibitors or strong inducers of P-glycoprotein (P-gp, e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus [HIV]-protease inhibitors, such as ritonavir) and/or Cytochrome P450 3A4 (CYP3A4)]; expected requirement for major surgery post-arthroplasty within 90 days; women Persons of childbearing potential who are not abstinent or do not use appropriate contraception or are breast-feeding; unable or unwilling to provide consent; previous participation in the HIPSTER trial; participation in another anticoagulant or antiplatelet study.

Primary Purpose

Prevention

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

McMaster UniversityOTHER

Collaborators

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) NetworkNETWORK

International Network of VENous Thromboembolism Clinical Research NetworksUNKNOWN

kesslerf@mcmaster.ca905-527-4322 ext. 40654

corrado.lodigiani@humanitas.it+39 0282244656